1. Finding melanoma drugs through a probabilistic knowledge graph
- Author
-
Michel Dumontier, Deborah L. McGuinness, Rui Yan, James P. McCusker, Jonathan S. Dordick, and Sylvia He
- Subjects
0301 basic medicine ,General Computer Science ,Systems biology ,Computational biology ,Bioinformatics ,Uncertainty reasoning ,lcsh:QA75.5-76.95 ,MALIGNANT-MELANOMA ,03 medical and health sciences ,LUNG-CANCER ,0302 clinical medicine ,Knowledge graphs ,Medicine ,Probabilistic analysis of algorithms ,COMPREHENSIVE RESOURCE ,CANCER-CELLS ,Melanoma ,GENE-EXPRESSION ,PROTEIN-INTERACTION DATABASE ,business.industry ,Drug repositioning ,Probabilistic logic ,medicine.disease ,APOPTOSIS ,Clinical trial ,METASTASES ,030104 developmental biology ,DISCOVERY ,030220 oncology & carcinogenesis ,Personalized medicine ,lcsh:Electronic computers. Computer science ,Skin cancer ,User interface ,business ,PHASE-II TRIAL - Abstract
Metastatic cutaneous melanoma is an aggressive skin cancer with some progression-slowing treatments but no known cure. The omics data explosion has created many possible drug candidates, however filtering criteria remain challenging, and systems biology approaches have become fragmented with many disconnected databases. Using drug, protein, and disease interactions, we built an evidence-weighted knowledge graph of integrated interactions. Our knowledge graph-based system, ReDrugS, can be used via an API or web interface, and has generated 25 high quality melanoma drug candidates. We show that probabilistic analysis of systems biology graphs increases drug candidate quality compared to non-probabilistic methods. Four of the 25 candidates are novel therapies, three of which have been tested with other cancers. All other candidates have current or completed clinical trials, or have been studied in in vivo or in vitro. This approach can be used to identify candidate therapies for use in research or personalized medicine.
- Published
- 2016
- Full Text
- View/download PDF